Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
JNJ-1900, an immune-stimulating radiation sensitizer designed to boost the results of hypofractionated radiation in small, focused areas, is being investigated in a part...
Pelabresib plus Rituxan improved spleen measurement and signs in untreated myelofibrosis, assembly the primary objective of the MANIFEST-2 trial.Pelabresib (CPI-0610) remedy together with...
